<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00307502</url>
  </required_header>
  <id_info>
    <org_study_id>PK-TRANSVERSAL</org_study_id>
    <secondary_id>2004-001516-32</secondary_id>
    <nct_id>NCT00307502</nct_id>
  </id_info>
  <brief_title>Study to Determine the Pharmacokinetic Behavior of Antiretroviral Drugs in Patients Infected by HIV</brief_title>
  <official_title>Cross-sectional Study for the Characterisation of the Pharmacokinetic Parameters of Protease Inhibitors and Non-nucleoside Analog Reverse Transcriptase Inhibitors in the Spanish Population of HIV-infected Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Germans Trias i Pujol Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundacio Lluita Contra la SIDA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Germans Trias i Pujol Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to characterise the pharmacokinetic profiles of non-nucleoside
      analog reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs), and the
      influence of the individual characteristics on the pharmacokinetic parameters in the Spanish
      population of HIV-infected subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The antiretrovirals were administered conventionally according to fixed dosage systems, or
      depending on the weight of the individual in the case of certain agents. However, the plasma
      levels of antiretrovirals following the administration of a fixed dose present a marked
      interindividual variability. Moreover, a significant proportion of the patients on treatment
      with PIs presented plasma levels regarded as suboptimal in previous studies.

      Moreover, for the correct modification of the dosage of a drug, populational data on its
      pharmacokinetic behaviour during the dosing interval is required. Only by integrating this
      information with the specific characteristics of each individual is it possible, using
      mathematical models, to estimate the effect that a modification of the dosage of the drug
      would have on its plasma concentration. However, populational data on the pharmacokinetic
      behaviour of antiretroviral agents are still very limited at this moment, and have not always
      been obtained in populations similar to the one to which they are to be applied.

      Thus, knowing the pharmacokinetic behaviour of the antiretroviral agents in our population
      and the influence of certain individual characteristics on this behaviour may be of great
      interest, since only in this way will we be able to tailor the dosage of antiretrovirals
      reliably in our patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint is the plasma concentration of the PI/NNRTI drugs (Ka absorption constant, CI: plasma clearance, Vd: volume of distribution).</measure>
    <time_frame>In the 12 hour (h) pharmacokinetic curve</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Demographic: race, gender, age</measure>
    <time_frame>In the 12 h pharmacokinetic curve</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical: weight, height, liver/renal impairment, HIV infection stage, tobacco/alcohol consumption</measure>
    <time_frame>In the 12 h pharmacokinetic curve</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>In the 12 h pharmacokinetic curve</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory: creatinine, albumin, Quick Index, bilirubin, GOT, GPT, GGT, FA, CD4 lymphocyte count, HIV viral load, HBsAg and anti-HCV, alpha acid glycoprotein</measure>
    <time_frame>In the 12 h pharmacokinetic curve</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antiretroviral and concomitant treatment, adherence (number of doses omitted in the last two weeks)</measure>
    <time_frame>In the 12 h pharmacokinetic curve</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: maximum concentration (Cmax), time to maximum concentration (Tmax), plasma concentration at the end of the posology interval (Ctrough), half-life (T1/2), area under the curve (ABC)</measure>
    <time_frame>In the 12 h pharmacokinetic curve</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genetic study of polymorphism of CYP3A4 and P-glycoprotein</measure>
    <time_frame>In the 12 h pharmacokinetic curve</time_frame>
  </secondary_outcome>
  <number_of_arms>11</number_of_arms>
  <enrollment type="Anticipated">675</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>NVP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nevirapine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EFV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Efavirenz</description>
  </arm_group>
  <arm_group>
    <arm_group_label>INV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Indinavir/ritonavir</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NFV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nelfinavir</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SQV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Saquinavir/ritonavir</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LPV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lopinavir/ritonavir</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ATV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atazanavir</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ATV/rtv</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atazanavir/ritonavir</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fos-APV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fos-amprenavir/ritonavir</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TPV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tipranavir/ritonavir</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DRV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Darunavir/ritonavir</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nevirapine</intervention_name>
    <description>tablets 200 mg, 400 mg/day</description>
    <arm_group_label>NVP</arm_group_label>
    <other_name>Viramune</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Efavirenz</intervention_name>
    <description>tablets 600 mg, 600 mg/day</description>
    <arm_group_label>EFV</arm_group_label>
    <other_name>Sustiva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indinavir/ritonavir</intervention_name>
    <description>Indinavir: capsules 400 mg, 1600 mg/day
Ritonavir: capsules 100 mg, 200 mg/day</description>
    <arm_group_label>INV</arm_group_label>
    <other_name>Crixivan/norvir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nelfinavir</intervention_name>
    <description>tablets 250 mg, 2500 mg/day</description>
    <arm_group_label>NFV</arm_group_label>
    <other_name>Viracept</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saquinavir/ritonavir</intervention_name>
    <description>Saquinavir: tablets 500 mg, 2000 mg/day
Ritonavir: tablets 100 mg, 200 mg/day</description>
    <arm_group_label>SQV</arm_group_label>
    <other_name>Invirase/Norvir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lopinavir/ritonavir</intervention_name>
    <description>tablets lopinavir 200 mg + ritonavir 50 mg, 800/200 mg/day</description>
    <arm_group_label>LPV</arm_group_label>
    <other_name>Kaletra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atazanavir</intervention_name>
    <description>capsules 200 mg, 400 mg/day</description>
    <arm_group_label>ATV</arm_group_label>
    <other_name>Reyataz</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atazanavir/ritonavir</intervention_name>
    <description>Atazanavir: capsules 150 mg, 300 mg/day
Ritonavir: capsules 100 mg, 200 mg/day</description>
    <arm_group_label>ATV/rtv</arm_group_label>
    <other_name>Reyataz/Norvir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fos-amprenavir/ritonavir</intervention_name>
    <description>Fos-amprenavir: capsules 700 mg, 1400 mg/day
Ritonavir: capsules 100 mg, 200 mg/day</description>
    <arm_group_label>Fos-APV</arm_group_label>
    <other_name>Telzir/norvir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tipranavir/ ritonavir</intervention_name>
    <description>Tipranavir: tablets 250 mg, 1000 mg/day
Ritonavir: capsules 100 mg, 400 mg/day</description>
    <arm_group_label>TPV</arm_group_label>
    <other_name>Aptivus/Norvir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Darunavir/ritonavir</intervention_name>
    <description>Darunavir: tablets 300 mg, 1200 mg/day
Ritonavir: capsules 100 mg, 200 mg/day</description>
    <arm_group_label>DRV</arm_group_label>
    <other_name>Prezista/norvir</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age higher than 18 years.

          2. Documented HIV infection (at least one positive Western-blot)

          3. Stable antiretroviral treatment with PI or NNRTI, no changes over the last 4 weeks.

          4. Women may not be of fertile age (defined as at least one year from menopause or
             undergoing any surgical sterilisation technique), or negative pregnancy test.

        Exclusion Criteria:

          1. Subjects on treatment with more than one PI or with combinations of PI and NNRTI (the
             use of ritonavir in doses below 400 mg BID will not be regarded as a second PI).

          2. Treatment with other drugs with known significant pharmacological interactions with
             the investigational drug over the previous two weeks.

          3. Unsuitable adherence to treatment (one or more doses omitted in the last week, or two
             or more doses omitted in the last two weeks).

          4. Presence of clinical findings or a background of gastrointestinal disease or digestive
             surgery that may interfere in the pharmacokinetics of the medication.

          5. Active consumption of alcohol (&gt;50 grams/day) or illegal drugs (except cannabis).

          6. In the case of women, pregnancy or breastfeeding.

          7. Record or suspicion of inability to cooperate properly
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bonaventura Clotet, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lluita contra la Sida Foundation-HIV Unit</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Germans Trias i Pujol Hospital</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Figueres</name>
      <address>
        <city>Figueras</city>
        <state>Barcelona</state>
        <zip>17600</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundació Hospital-Asil de Granollers</name>
      <address>
        <city>Granollers</city>
        <state>Barcelona</state>
        <zip>08400</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Vic</name>
      <address>
        <city>Vic</city>
        <state>Barcelona</state>
        <zip>08500</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Sant Joan de Reus</name>
      <address>
        <city>Reus</city>
        <state>Tarragona</state>
        <zip>43201</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 27, 2006</study_first_submitted>
  <study_first_submitted_qc>March 27, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 28, 2006</study_first_posted>
  <last_update_submitted>February 22, 2010</last_update_submitted>
  <last_update_submitted_qc>February 22, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 23, 2010</last_update_posted>
  <responsible_party>
    <name_title>Lluita Sida Foundation</name_title>
    <organization>Lluita Sida Foundation</organization>
  </responsible_party>
  <keyword>protease inhibitors</keyword>
  <keyword>non-nucleoside analog reverse transcriptase inhibitors</keyword>
  <keyword>pharmacokinetic models</keyword>
  <keyword>treatment experienced</keyword>
  <keyword>HIV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Darunavir</mesh_term>
    <mesh_term>Atazanavir Sulfate</mesh_term>
    <mesh_term>HIV Protease Inhibitors</mesh_term>
    <mesh_term>Nelfinavir</mesh_term>
    <mesh_term>Indinavir</mesh_term>
    <mesh_term>Saquinavir</mesh_term>
    <mesh_term>Amprenavir</mesh_term>
    <mesh_term>Fosamprenavir</mesh_term>
    <mesh_term>Nevirapine</mesh_term>
    <mesh_term>Tipranavir</mesh_term>
    <mesh_term>Efavirenz</mesh_term>
    <mesh_term>Protease Inhibitors</mesh_term>
    <mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

